PM8002 in the Treatment of Patients With Advanced Solid Tumors
Recruiting in Palo Alto (17 mi)
+38 other locations
YG
Overseen byYe Guo
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 1 & 2
Recruiting
Sponsor: Biotheus Inc.
No Placebo Group
Trial Summary
What is the purpose of this trial?
This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of PM8002, a PD-L1/VEGF bispecific antibody, as a single agent in adult subjects with advanced solid tumors.
Research Team
YG
Ye Guo
Principal Investigator
Shanghai Orient Hospital
Eligibility Criteria
Inclusion Criteria
Voluntary participation in clinical study; fully understand the study and sign informed consent voluntarily; willing to follow and able to complete all test procedures;
Male or female aged 18 to 75 years;
Patients with malignant tumor confirmed by histology or cytology;
See 5 more
Treatment Details
Participant Groups
1Treatment groups
Experimental Treatment
Group I: PM8002Experimental Treatment1 Intervention
PM8002 IV every 2 weeks(q2w) or every 3 weeks(q3w)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Biotheus Inc.
Lead Sponsor
Trials
21
Recruited
5,100+